Abstract
Understanding the demand for hospital beds for COVID-19 patients is key for decision-making and planning mitigation strategies, as overwhelming healthcare systems has critical consequences for disease mortality. However, accurately mapping the time-to-event of hospital outcomes, such as the length-of-stay in the ICU, requires understanding patient trajectories while adjusting for covariates and observation bias, such as incomplete data. Standard methods, like the Kaplan-Meier estimator, require prior assumptions that are untenable given current knowledge. Using real-time surveillance data from the first weeks of the COVID-19 epidemic in Galicia (Spain), we aimed to model the time-to-event and event probabilities of patients hospitalized, without parametric priors and adjusting for individual covariates. We applied a nonparametric Mixture Cure Model and compared its performance in estimating hospital ward/ICU lengths-of-stay to the performances of commonly used methods to estimate survival. We showed that the proposed model outperformed standard approaches, providing more accurate ICU and hospital ward length-of-stay estimates. Finally, we applied our model estimates to simulate COVID-19 hospital demand using a Monte Carlo algorithm. We provided evidence that adjusting for sex, generally overlooked in prediction models, together with age is key for accurately forecasting ICU occupancy, as well as discharge or death outcomes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
ALC was sponsored by the BEATRIZ GALINDO JUNIOR Spanish from MICINN (Ministerio de Ciencia, Innovación y Universidades) with reference BGP18/00154. ALC, MAJ and RC acknowledge partial support by the MINECO (Ministerio de Economía y Competitividad) Grant MTM2014–52876-R (EU ERDF support included) and the MICINN Grant MTM2017–82724-R (EU ERDF support included) and partial support of Xunta de Galicia (Centro Singular de Investigación de Galicia accreditation ED431G/01 2016–2019 and Grupos de Referencia Competitiva CN2012/130 and ED431C2016–015) and the European Union (European Regional Development Fu–d – ERDF). PMD is a current recipient of the Grant of Excellence for postdoctoral studies by the Ramón Areces Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
CEIC Hospital Clínico San Carlos of Madrid (Spain). Code C.I. 20/280-E_COVID
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data was provided for analysis by the regional public health authority of Galicia (Spain), Dirección Xeral de Saúde Pública https://www.sergas.es/Saude-publica
